Business
Soligenix to Present at BIO Investment & Growth Summit
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President & Chief Executive Officer will deliver a corporate presentation at the BIO Investment & Growth Summit at 3:00 PM on Monday, March 2. The BIO Investment & Growth Summit, held March 2 to 3 at Eden Roc Miami Beach, in Miami Beach,
About this update from Soligenix, Inc.
[{"type":"text","content":"PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President & Chief Executive Officer will deliver a corporate presentation at the BIO Investment & Growth Summit at 3:00 PM on Monday, March 2. The BIO Investment & Growth Summit, held March 2 to 3 at Eden Roc Miami Beach, in Miami Beach, Florida, will include innovative programs, one-on-one meetings, and company presentations. For more information please refer to the conference website at https://bigs.bio.org/.","length":735,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Soligenix, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Soligenix, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0bSTAeYRTNnLNEjUJiiRHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/1768046/Soligenix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platforms. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact [email protected].","length":241,"tagName":"p"},{"type":"text","content":"About Soligenix, Inc.","length":21,"tagName":"p"},{"type":"text","content":"Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization...